170 completed, 67 unknown, 40 terminated, 36 recruiting. 125 Phase 2, 64 Phase 1, 56 Phase 3, 45 Not applicable, 22 Phase 4.
Follow this condition Literature Review of Skin Diseases, Vesiculobullous trials Research Report on Skin Diseases, Vesiculobullous
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis Site specific standard of care comparison - Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis | Withdrawn | Massachusetts General Hospital | 2030-01-01 | 2026-01-16 | ||
| Rituximab With Corticosteroids Versus Corticosteroids Plus Azathioprine for Moderate-to-Severe Pemphigus Vulgaris Rituxan (rituximab), Azathioprine (AZA)' plus corticosteroids - Pemphigus Vulgaris, Rituximab (RTx) | Early Phase 1 | Not yet recruiting | Khyber Teaching Hospital | 92 | 2026-12-02 | 2026-08-18 |
| An Open Label Extension Safety Study to Evaluate SD-101 in Epidermolysis Bullosa SD-101 Dermal Cream (6%) - Epidermolysis Bullosa (EB) | Phase 3 | Not yet recruiting | Paradigm Therapeutics | 80 | 2026-11-15 | 2026-09-09 |
| Phase 4 Master Protocol for Patients Prescribed Prademagene Zamikeracel for the Treatment of Wounds Non-conforming pz-cel surgical application to RDEB wounds, Additional biopsies, Pz-cel surgical application to DEB wounds - Epidermolysis Bullosa (EB), Recessive Dystrophic Epidermolysis Bullosa (RDEB) | Phase 4 | Not yet recruiting | Abeona Therapeutics, Inc | 100 | 2026-11-01 | 2026-08-06 |
| Emerging Indications for Hyperbaric Oxygen Treatment Hyperbaric oxygen treatment (HBOT), 100% Oxygen - Post-COVID-19 Condition, Ulcerative Colitis | Phase 4 | Not yet recruiting | Jay C. Buckey Jr. | 100 | 2026-11-01 | 2026-09-09 |
| A Study to Evaluate ENERGI-F703EB Cream in Epidermolysis Bullosa ENERGI-F703EB Cream, Matched vehicle cream - Epidermolysis Bullosa (EB), Junctional Epidermolysis Bullosa | Phase 2 | Recruiting | Energenesis Biomedical Co., Ltd. | 24 | 2026-10-08 | 2026-10-05 |
| NanoSALV vs Standard Topical Care Pathway in Sports-Related Skin Lesions NanoSALV Catalytic, Standard Topical Care Pathway - Blister of Foot, Blister | Phase 3 | Not yet recruiting | Shahab Alizadeh | 100 | 2026-10-01 | 2026-09-08 |
| Filsuvez in Moderate-to-Severe Epidermolysis Bullosa Simplex Filsuvez - Epidermolysis Bullosa Simplex | Phase 2 | Not yet recruiting | Stanford University | 10 | 2026-10-01 | 2026-08-10 |
| Subconjunctival Humira for Boston Keratoprosthesis Adalimumab Injection - Penetrating Keratoplasty, Multiple Graft Failure | Phase 1 | Not yet recruiting | Massachusetts Eye and Ear Infirmary | 8 | 2026-10-01 | 2026-08-31 |
| Comparison of Segmental Body Composition Characteristics in Lipedema and Obesity Bioelectrical Impedance Analysis, Numeric Rating Scale, Lower Extremity Functional Scale - Lipedema, Obesity | Recruiting | Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey | 200 | 2026-09-20 | 2026-10-16 | |
| Impact of Body Positioning on EndoFLIP Measurements: A Comparative Study of Supine and Left Lateral Decubitus Positions EndoFlip - Dysphagia, Esophageal Stricture | Not applicable | Recruiting | Johns Hopkins University | 25 | 2026-07-24 | 2026-08-24 |
| Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa SD-101 Dermal Cream (6%), Vehicle (SD-101 0%) - Epidermolysis Bullosa (EB) | Phase 3 | Recruiting | Paradigm Therapeutics | 80 | 2026-07-21 | 2026-10-15 |
| Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART) Efgartigimod - Epidermolysis Bullosa (EB), Epidermolysis Bullosa Acquisita | Phase 1 / Phase 2 | Not yet recruiting | M. Peter Marinkovich | 18 | 2026-07-01 | 2026-05-05 |
| Treatment of Dysphagia in Patients With Dystrophic Epidermolysis Bullosa With Budesonide: a Retrospective Bicentric Study Nice - Paris St Louis / Necker (EBUDE Study) The retrospective data collected will be entered into an eCRF and then analyzed centrally - Recessive Dystrophic Epidermolysis Bullosa, Dysphagia | Not applicable | Not yet recruiting | Centre Hospitalier Universitaire de Nice | 15 | 2026-07-01 | 2026-07-06 |
| Investigation of Systemic Inflammation Markers in Lipedema Clinical parameters, Laboratory parameters - Lipedema, Inflamation | Completed | Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey | 192 | 2026-06-01 | 2026-08-26 | |
| A Study to Investigate Safety and Efficacy of KB111 for the Treatment of Hailey-Hailey Disease KB111 - Hailey Hailey Disease, Skin Diseases | Early Phase 1 | Recruiting | Krystal Biotech, Inc. | 7 | 2026-05-06 | 2026-07-21 |
| Association Between Disease Severity and Clinical, Histopathological, and Eosinophilic Markers in Patients With Bullous Pemphigoid (BP-EPIC) Bullous Pemphigoid (BP) | Active not recruiting | Istanbul Training and Research Hospital | 50 | 2026-05-04 | 2026-06-16 | |
| A Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study TCP-25 gel, Vehicle (placebo) - Epidermolysis Bullosa (EB), Dystrophic Epidermolysis Bullosa | Phase 2 | Recruiting | Xinnate AB | 32 | 2026-01-30 | 2026-08-12 |
| HLA-B*58:01-Guided Therapy for Gout: Effectiveness, Safety, and Cost-Effectiveness HLA-B*58:01 Genotyping, Allopurinol Tablet, Febuxostat - Gout Initiating Urate-loweringUrate-lowering Therapy, Gout Arthritis | Phase 4 | Not yet recruiting | Haiphong University of Medicine and Pharmacy | 228 | 2026-01-20 | 2026-01-27 |
| CD19 CAR-T Therapy for Refractory Pemphigus Vulgaris Autologous CD19 CAR-T cells - Pemphigus Vulgaris | Not applicable | Recruiting | Jinbo Chen | 3 | 2026-01-15 | 2026-07-02 |
Showing 20 of 377. Sign in to see all of them.
Epidermolysis Bullosa (80) · Epidermolysis Bullosa Dystrophica (77) · Pemphigus (73) · Pemphigoid, Bullous (62) · Stevens-Johnson Syndrome (40) · Blister (32) · Skin Diseases (21) · Epidermolysis Bullosa Simplex (20) · Epidermolysis Bullosa, Junctional (16) · Pemphigoid, Benign Mucous Membrane (16) · Erythema Multiforme (15) · Autoimmune Diseases (11) · Pruritus (11) · Rare Diseases (10)
Skin and Connective Tissue Diseases (376) · Skin Diseases (356) · Immune System Diseases (182) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (163) · Genetic Diseases, Inborn (156) · Skin Diseases, Genetic (153) · Congenital Abnormalities (146) · Skin Abnormalities (141) · Autoimmune Diseases (132) · Connective Tissue Diseases (92) · Collagen Diseases (76) · Pathological Conditions, Signs and Symptoms (76) · Epidermolysis Bullosa (65) · Erythema (54)
Rituximab (14) · Prednisone (9) · Mycophenolic Acid (7) · Blood Specimen Collection (6) · Cyclophosphamide (6) · Dapsone (6) · Gentamicins (6) · Azathioprine (5) · Methotrexate (5) · Ointments (5) · diacerein (5) · dupilumab (5) · fludarabine (5) · Clobetasol (4) · Infliximab (4)
Centre Hospitalier Universitaire de Nice (12) · Assistance Publique - Hôpitaux de Paris (10) · Stanford University (10) · University Hospital, Rouen (10) · Krystal Biotech, Inc. (8) · Assiut University (6) · CHU de Reims (6) · Abeona Therapeutics, Inc (5) · Northwestern University (5) · University of Southern California (5) · argenx (5) · Chao Ji (4) · Masonic Cancer Center, University of Minnesota (4) · National Institute of Allergy and Infectious Diseases (NIAID) (4) · Scioderm, Inc. (4)
United States (147) · France (76) · Germany (33) · China (25) · Israel (23) · Spain (23) · United Kingdom (21) · Australia (20) · Italy (20) · Austria (18) · Greece (16) · Japan (15) · Poland (15) · Turkey (Türkiye) (15) · Canada (14)
David Woodley, MD (3) · Jakub Tolar, MD, PhD (3) · Jean Tang, MD, PhD (3) · Alfred Lane, MD (2) · Alfred T Lane (2) · Amit Pandya, MD (2) · Antoni Gostynski, MD, PhD (2) · Christine Bodemer, MD, PhD (2) · Detlef Zillikens, MD (2)
PMID 19357707, PMID 31541747, PMID 35234826, PMID 11511292, PMID 11912510, PMID 12558848, PMID 12648223, PMID 14734878, PMID 15161841, PMID 15238912, PMID 15287367, PMID 16250204, PMID 16583638, PMID 16702494, PMID 1720352, PMID 17687130, PMID 18087004, PMID 18209165, PMID 18571597, PMID 18602282, PMID 18692246, PMID 18854726, PMID 18948357, PMID 19241467, PMID 19267394, PMID 20410913, PMID 20466177, PMID 20818854, PMID 21167320, PMID 21877134, PMID 21955378, PMID 22026362, PMID 23483391, PMID 23651789, PMID 24433179, PMID 25123295, PMID 25431026, PMID 25443754, PMID 25607554, PMID 25832646, PMID 26194911, PMID 26297574, PMID 26543381, PMID 26597100, PMID 26802230, PMID 27015660, PMID 27106261, PMID 27287854, PMID 27386970, PMID 27716293
2014 (5), 2017 (3), 2016 (2), 2018 (2), 2023 (2), 2015 (1), 2019 (1), 3UM1AI068614-14S1 (1), P01GM095467 (1), R01AG038673 (1), R01AR055914 (1), R01AR076089 (1)